- In March 2026, Hims & Hers Health announced a collaboration with Novo Nordisk to offer eligible customers a broad range of FDA-approved GLP-1 medications, including the Wegovy pill, alongside a new weight loss membership featuring 24/7 provider access and personalized support starting at US$39 for the first month and US$149 thereafter.
- This partnership expands Hims & Hers’ presence in the fast-growing medical weight management category by pairing branded GLP-1 therapies with a subscription-based care model that could deepen customer engagement across its telehealth platform.
- Next, we’ll examine how adding Novo Nordisk’s GLP-1 portfolio and a structured weight loss membership could influence Hims & Hers’ long-term investment narrative.
Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
Hims & Hers Health Investment Narrative Recap
To own Hims & Hers, you need to believe its telehealth model can turn high‑demand categories like weight management into durable, recurring relationships across multiple conditions. The Novo Nordisk GLP‑1 collaboration sharpens that story by giving customers branded options and a structured membership, potentially reinforcing the current catalyst around subscription growth, while also amplifying the key risk that heavy reliance on weight loss exposes the business to regulatory shifts and changing attitudes in a very visible category.
The March 2026 announcement builds directly on the April 2025 long‑term collaboration with Novo Nordisk, which first brought Wegovy access onto the platform at a unified US$599 per month. Together, these moves connect the company’s weight loss ambitions with its broader push into daily, membership‑driven care, sitting alongside newer launches like menopause and at‑home lab testing as it works to deepen engagement and diversify beyond a single blockbuster therapy.
Yet while this looks like progress, investors should also weigh how concentrated exposure to GLP‑1s could backfire if...
Read the full narrative on Hims & Hers Health (it's free!)
Hims & Hers Health's narrative projects $3.6 billion revenue and $248.0 million earnings by 2029. This requires 15.6% yearly revenue growth and about a $119.6 million earnings increase from $128.4 million today.
Uncover how Hims & Hers Health's forecasts yield a $23.69 fair value, a 14% upside to its current price.
Exploring Other Perspectives
Some of the lowest‑priced analysts see far more risk here, even before this GLP‑1 news, expecting only about US$3.1 billion of revenue and US$268.9 million of earnings by 2028, so you should compare their concerns about regulatory pressure and pricing power with more optimistic views and decide which narrative feels closer to your own expectations.
Explore 56 other fair value estimates on Hims & Hers Health - why the stock might be worth over 8x more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Hims & Hers Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.
Contemplating Other Strategies?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Find 58 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com